Baillie Gifford
Search results
Jun 3, 2024 · Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. Our cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology .
Apr 11, 2024 · But perhaps the most astonishing feature of biology is that it runs on digital code in the form of DNA, which makes it possible for us to imagine building such living machines. The code is made up of As, Ts, Cs, and Gs, and we can read and write it to program cells like we program computers.
Apr 11, 2024 · Designing the best organisms requires a different sort of factory, one where the best tools in automation, analytics, and software can all work in sync. The Bioworks foundries are automating and scaling the process of organism design, allowing engineers to prototype thousands of biological designs.
Ginkgo Bioworks, Inc. | 89,060 followers on LinkedIn. Making biology easier to engineer. | At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to...
Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Oct 24, 2018 · Ginkgo Bioworks Is Turning Human Cells Into On-Demand Factories The synthetic biology company has opened a new foundry to churn out mammal cells, first for drug development, and later to build ...
Jun 3, 2024 · Ginkgo is your end-to-end synthetic biology R&D partner. Browse a selection of our partner projects and case studies to explore how biology is being used across industries. Speak to our team today to access more.
May 11, 2021 · Ginkgo Bioworks is going public via a merger with former MGM CEO Harry Sloan's SPAC in a deal that values the biotech company at $15 billion.
Aug 24, 2021 · The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic biology will transform the manufacture of ...
